Serious COVID vaccine injuries are rare
Most COVID vaccine reactions, such as a sore arm or fatigue, pass quickly. Serious injuries are rare, but they are real and depend on the product. Persistent symptoms deserve careful investigation. Finding an immune change does not, by itself, show widespread immune damage.
On this page
Known risks differ between products
Soreness, fatigue and fever usually pass quickly. mRNA vaccines can rarely cause myocarditis. Particular adenovirus-vector products caused thrombosis with low platelets, a different serious risk. An older product’s risk is not automatically a current mRNA dose’s risk. Rare does not mean mild or unimportant to someone affected.
A safety signal needs follow-up
Reports, clinical case review and active comparisons work together. A signal is neither a final verdict nor something to ignore. The deaths page explains why reports and arbitrary underreporting multipliers cannot establish a population injury count.
What an early trial analysis found
A later analysis of early Pfizer and Moderna trials found 12.5 extra serious health events of particular concern per 10,000 participants, with a study range of 2.1–22.9. That finding deserves examination. It counted events, not necessarily different injured people, and did not measure permanent disability or deaths alone. Researchers did not have the detailed records for each participant, and follow-up was short. The number cannot simply be multiplied by every dose given today.
Persistent symptoms deserve better answers
A 2025 Yale-associated preprint compared 42 participants reporting persistent symptoms with 22 vaccinated controls. Immune differences warranted further investigation. This small selected sample cannot estimate how common such illness is or establish the cause of every symptom. Patients’ experiences should not be dismissed.
Antibody changes do not establish immune collapse
Repeated-dose studies found changes in spike-specific IgG4, one antibody type. Later small studies also found associations with breakthrough infection. Those observations do not demonstrate AIDS, generalized immune failure or cancer. An immune measurement and a clinical diagnosis are different outcomes.
Compare benefits and harms in the same population
Useful comparisons match age, product, dose, outcome and follow-up. Historical adverse-event counts cannot simply be multiplied by all doses administered today. The COVID overview covers protection; personal circumstances and local recommendations belong in a clinical discussion.
Most COVID vaccine reactions, such as a sore arm or fatigue, pass quickly.
Keep in mind
- The findings apply to the vaccines, populations and outcomes studied. Personal recommendations depend on your health and current local guidance.
Sources you can check
Publication links open in a new tab, so you can keep your place here.
COMIRNATY — Prescribing Information (opens in a new tab)
FDA
Product-specific reactions and warnings. Historical trial results in a current label are not all measurements of the current formulation.
Return to reading ↑FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis (opens in a new tab)
FDA, June 2025
Observed 2023–24-formulation incidence in days 1–7 is not an excess-risk estimate. Persistent MRI findings have uncertain long-term meaning.
Return to reading ↑Evidence Review of the Adverse Effects of COVID-19 Vaccination (opens in a new tab)
National Academies, 2024
Conclusions are specific to vaccine product and clinical outcome.
Return to reading ↑COVID-19 Vaccine Safety Surveillance (opens in a new tab)
FDA
Explains how reports and comparative monitoring identify safety signals.
Return to reading ↑Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination (opens in a new tab)
medRxiv, 2025 preprint
Exploratory comparison of 42 symptomatic participants and 22 vaccinated controls; cannot measure population incidence or establish each symptom’s cause.
Return to reading ↑Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination (opens in a new tab)
Science Immunology, 2023
Measures antibody changes, not generalized immune failure or cancer.
Return to reading ↑Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk (opens in a new tab)
Scientific Reports, 2026
Small cohorts; an antibody association with breakthrough infection is not proof of AIDS, cancer or a causal risk per dose.
Return to reading ↑Interim Estimated Effectiveness of 2025–2026 COVID-19 Vaccines in Adults Using a Test-Negative Design (opens in a new tab)
JAMA Network Open, 2026
US immunocompetent adults, September–December 2025; compares a current-season dose with none, with short follow-up.
Return to reading ↑Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (opens in a new tab)
Vaccine
It combines several diagnoses and counts events, not necessarily different people or permanent injuries. Individual participant records were unavailable. It cannot be applied to all current vaccines and doses.
Return to reading ↑VAERS data: interpretation and limitations (opens in a new tab)
CDC / FDA
Reports after vaccination help flag possible problems. On their own, they cannot establish what caused an event or how often a vaccine caused it.
Return to reading ↑
Detailed research notes and source data
Our longer notes explain how we checked the studies, including disagreements and documents we could not get.
Download the detailed research notes →More research notes: vaccine risks →
More research notes: supporting evidence →
Something unclear or missing?
You can save a feedback note to share with the site owner. The form saves a file on your device; it does not send it to us.
Save a feedback note →About this draft
These pages have not completed expert review. For personal vaccine advice, talk to a clinician who knows your circumstances.
Research checked: . Wording reviewed: 2026-10-15. Version: vaccine-2026-10-15.
We revisit the page when new evidence or corrections change the answer. A public history of corrections is not available yet.